Stay updated on Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, indicating a small update to the page metadata or formatting; the change does not modify the study details or primary content.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe study record now shows Results Posted on 2026-04-29 with updated outcomes (PFS, ORR, OS, adverse events) and provides the Informed Consent Form PDF and Study Protocol/SAP; prior entries like Results Submitted and shorter timeframes have been replaced with the new posted-results status and extended timeframes.SummaryDifference1%

- Check28 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a minor site release rather than a change to the underlying study content.SummaryDifference0.0%

- Check35 days agoChange DetectedThe page revision changed from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check64 days agoChange DetectedRevision: v3.5.0 has been added to the page, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check78 days agoChange DetectedRevision: v3.4.3 replaces v3.4.2 on the page.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.